Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Tanespimycin (17-AAG) Chemical Structure

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Size Price Stock Quantity  
In DMSO USD 195 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

8 Customer Reviews

  • (A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.

    PNAS, 2011, 108: 7535-40. Tanespimycin (17-AAG) purchased from Selleck.

    Four types of the colon cancer cells with indicated K-Ras phenotype were incubated with indicated concentration of 17-AAG for 24 h, which were then analyzed for protein expression by WB.

    Oncotarget 2014 5, 4269-82. Tanespimycin (17-AAG) purchased from Selleck.

  • Western blot analysis of immunoprecipitated Hsp90/BIP complexes in MOLT-4 (T-ALL) and RS4;11 (B-ALL) treated for 22 h with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. 500 μg of protein lysates were immunoprecipitated with anti-Hsp90 antibody. Relative Induction values (Rel.Ind.) were obtained by normalizing to Hsp90 bands density. 17-AAG: tanespimycin.

    Oncotarget, 2015, 51: S659-S660. Tanespimycin (17-AAG) purchased from Selleck.

    Co-IP analyses of direct interaction between HSP90 and HIF-1α in 17-AAG (5 μM)-treated HSCs using antibodies against HSP90, HIF-1α or IgG (n = 2).

    Br J Pharmacol, 2017, 174(5):409-423. Tanespimycin (17-AAG) purchased from Selleck.

  • UPR modulators destabilize mSmoM2. NIH 3T3 cells expressing mSmoM2 protein were treated with HSP90 inhibitors 17-AAG (50 uM and 100 uM) and SNX-2112 (25 uM and 50 uM) and the proteasome inhibitor bortezomib (25 uM and 50 uM) for 4 h prior to lysis. DMSO was the vehicle control. Western blotting of whole-cell lysates revealed mSmoM2 protein to be destabilized in response to HSP-90 inhibitors but not in response to bortezomib. Tubulin was the loading control. CHOP results indicate ER stress.

    Mol Cell Biol 2013 33(12), 2375-87. Tanespimycin (17-AAG) purchased from Selleck.

    Treatment with an Hsp90 inhibitor results in a dose-dependent decrease in complex IV activity. A, because Hsp90 levels were reduced by 80%, in PINK1 null dopaminergic neuronal cells, the effects of specific inhibition of Hsp90 using 17-AAG were analyzed in wild-type neuronal cells. Both complex IV activity and Hsp60 levels were decreased significantly in 17-AAG-treated cells in a dose-dependent manner. B, in contrast, 17-AAG treatment did not affect expression of Hsp90 and LRPPRC.

    J Biol Chem 2012 287, 44109-20. Tanespimycin (17-AAG) purchased from Selleck.

  • SKBR3 cells were treated with FW-04-806 at 10, 20, 40 uM for 24 h; 17AAG was used as a positive control at 1 and 2 uM. Hsp70, Hsp90, and Cdc37 protein level were analyzed with western blotting using relevant antibodies.

    Mol Cancer 2014 13, 150. Tanespimycin (17-AAG) purchased from Selleck.

    Hsp90 is up-regulated during aging. Whole-cell extracts were prepared from young (PD 20) and old (PD 40) HFSN1 cells. c HFSN1 cells (PD 40) were treated with different concentration of the Hsp90 inhibitor (17-AAG) and then re-incubated for 24 h. Whole-cell extracts were prepared and analyzed by western blot using the indicated antibodies.

    Age 2013 35, 549-62. Tanespimycin (17-AAG) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.
Features Displays very low toxicity toward normal cells.
Targets
HSP90 [1]
(Cell-free assay)
5 nM
In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. [1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. [2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NIWxc3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPBUGtKSzVyPUCuNFAxOzB|IN88US=> Ml7RV2FPT0WU
IST-MEL1 NYrze3BCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\qWZpKSzVyPUCuNFAxPDB5IN88US=> M2jSXnNCVkeHUh?=
NCI-SNU-1 MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwMECyNFch|ryP Mn;WV2FPT0WU
FADU MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzlTWM2OD1yLkCwNlA6KM7:TR?= Mn3lV2FPT0WU
C32 Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX3UoZKSzVyPUCuNFA{ODRizszN M2rPdHNCVkeHUh?=
D-566MG NHLQW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:zTWM2OD1yLkCwN|kh|ryP MV7TRW5ITVJ?
LXF-289 NHT1XZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwMEC0NVkh|ryP MXXTRW5ITVJ?
HGC-27 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHS1SXdKSzVyPUCuNFA2OSEQvF2= M1K2NHNCVkeHUh?=
RPMI-7951 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zWNGlEPTB;MD6wNFcyPyEQvF2= NF76SZJUSU6JRWK=
HSC-3 M1zLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL4XmZKSzVyPUCuNFA6OjlizszN M1;5TXNCVkeHUh?=
MIA-PaCa-2 M1nrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfxN4Q1UUN3ME2wMlAyODB7IN88US=> MmK2V2FPT0WU
KS-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfqTWM2OD1yLkCxN|U2KM7:TR?= M3j2[HNCVkeHUh?=
CAL-51 M1HqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMEG0NFUh|ryP MWPTRW5ITVJ?
MDA-MB-361 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnMfmhkUUN3ME2wMlAyPDl3IN88US=> NY\TdmY6W0GQR1XS
TI-73 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1e5VGlEPTB;MD6wNVc6PiEQvF2= M2jUdHNCVkeHUh?=
AGS MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnl[IlKSzVyPUCuNFE6OzhizszN MVXTRW5ITVJ?
NCI-H460 NWDZWGpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfteHJKSzVyPUCuNFE6PzRizszN MUnTRW5ITVJ?
A204 M3rkbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWH0cXV4UUN3ME2wMlAzOjR7IN88US=> NYLvc2x3W0GQR1XS
CHL-1 M13CdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTmTWM2OD1yLkCyNlUyKM7:TR?= MVzTRW5ITVJ?
DU-4475 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwMEKyOlEh|ryP NIXUe|BUSU6JRWK=
CGTH-W-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXrTWM2OD1yLkCyN|Q6KM7:TR?= MmDyV2FPT0WU
HCC2218 NV3ZeIZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\MT4xKSzVyPUCuNFI1QTRizszN M2Tm[3NCVkeHUh?=
A2780 NW\hfYhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMEK1N|Eh|ryP M4L3XXNCVkeHUh?=
NCI-H720 M{TIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nCS2lEPTB;MD6wNlU1PiEQvF2= M2L4WXNCVkeHUh?=
NCI-N87 MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7WN3hKSzVyPUCuNFI2QTNizszN NYfHcWxCW0GQR1XS
CHP-212 MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jyNmlEPTB;MD6wNlYzQCEQvF2= MmO5V2FPT0WU
NCI-H23 NHXXfIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXz0R3F4UUN3ME2wMlAzPjZ3IN88US=> M2PyenNCVkeHUh?=
D-263MG MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTnOFROUUN3ME2wMlAzPzh4IN88US=> M3zSNHNCVkeHUh?=
ME-180 NUjQNmRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zYOGlEPTB;MD6wNlg6OSEQvF2= M3zJVnNCVkeHUh?=
SW982 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;1PGlEPTB;MD6wNlk6QSEQvF2= NUXlVZJRW0GQR1XS
OE19 M{DYdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DSNWlEPTB;MD6wN|A4PyEQvF2= NWTNUXJuW0GQR1XS
SK-LU-1 M2\RNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMEOwPFIh|ryP NIXBfFlUSU6JRWK=
H4 MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHETWM2OD1yLkCzNFkh|ryP NV7hU5FRW0GQR1XS
HT-144 MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPXTWM2OD1yLkCzNFk{KM7:TR?= MmP4V2FPT0WU
SK-UT-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor4TWM2OD1yLkCzNVc5KM7:TR?= M{LGXHNCVkeHUh?=
D-336MG MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwMEOzNFkh|ryP M{\oUHNCVkeHUh?=
MDA-MB-175-VII NV\odo9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjxbXgyUUN3ME2wMlA{OzV2IN88US=> NFLo[|hUSU6JRWK=
GAMG MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHLd29KSzVyPUCuNFM1OzVizszN NV\qb|lIW0GQR1XS
CP50-MEL-B NWO1OpV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fn[GlEPTB;MD6wN|Q2KM7:TR?= NGfrUHpUSU6JRWK=
OVCAR-5 NGT2[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LCcWlEPTB;MD6wN|Q5KM7:TR?= NHTLc4FUSU6JRWK=
SK-MES-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\iOJpKSzVyPUCuNFM3ODZizszN M3HJ[XNCVkeHUh?=
VM-CUB-1 NYPt[m1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nz[2lEPTB;MD6wN|Y2PyEQvF2= NEHaUHVUSU6JRWK=
WM-115 MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:3TWM2OD1yLkCzO|YzKM7:TR?= MWjTRW5ITVJ?
DSH1 MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnjZ|BKSzVyPUCuNFM5ODdizszN NV3TUohiW0GQR1XS
Becker MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\HOWlEPTB;MD6wN|g5PSEQvF2= MVPTRW5ITVJ?
SW962 M2TsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2qwOGlEPTB;MD6wN|k1PSEQvF2= NY\Scm1pW0GQR1XS
TYK-nu MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjnVIRKSzVyPUCuNFM6QDVizszN NInibZdUSU6JRWK=
HO-1-N-1 NYHpNWw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHQeI5KSzVyPUCuNFQxOjFizszN M{XvWnNCVkeHUh?=
T98G Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rQdGlEPTB;MD6wOFExOyEQvF2= M3zWXHNCVkeHUh?=
ACN NYm3[lduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{C2fGlEPTB;MD6wOFE3OiEQvF2= NUeyd3dXW0GQR1XS
SW780 NGHEWVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\WPYZVUUN3ME2wMlA1OjB|IN88US=> M3XyenNCVkeHUh?=
Detroit562 MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwMESyN|kh|ryP MoTKV2FPT0WU
BB49-HNC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3Vb49KSzVyPUCuNFQzPDNizszN NUn5SHNkW0GQR1XS
HN NXHyNJRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwMESyO|Ih|ryP NE\BWVdUSU6JRWK=
H9 NFzIZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{W5WGlEPTB;MD6wOFM4OSEQvF2= NG\jSFJUSU6JRWK=
VA-ES-BJ MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvPTWM2OD1yLkC0OFQ4KM7:TR?= M3ewPHNCVkeHUh?=
MEL-JUSO MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13VOWlEPTB;MD6wOFQ4PSEQvF2= MmTVV2FPT0WU
BT-474 NFXmdWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnUSZZRUUN3ME2wMlA1PSEQvF2= NFnNPIxUSU6JRWK=
CaR-1 NH\sN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMES1OFkh|ryP NFfOUIlUSU6JRWK=
PSN1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXaTWM2OD1yLkC0OlA{KM7:TR?= MWLTRW5ITVJ?
KYSE-510 NFnXbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHHUmhKSzVyPUCuNFQ3PDlizszN NGPlbmFUSU6JRWK=
KP-4 M4DxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPBc4d{UUN3ME2wMlA1PzV|IN88US=> M4r1SHNCVkeHUh?=
KYSE-410 NHTaV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwMES3O|Ih|ryP MlvaV2FPT0WU
G-402 NELVeHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HaO2lEPTB;MD6wOFc5QSEQvF2= NWrPPVIzW0GQR1XS
DOK NGq4WmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMES5NFIh|ryP MXnTRW5ITVJ?
COR-L88 NHPtUVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTqTWM2OD1yLkC0PVEzKM7:TR?= NXHCeJRUW0GQR1XS
SKG-IIIa MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFqy[HZKSzVyPUCuNFQ6QDZizszN MVLTRW5ITVJ?
AN3-CA MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7XTWM2OD1yLkC1JO69VQ>? NVvSWZpjW0GQR1XS
SW48 Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXZUnB4UUN3ME2wMlA2ODN7IN88US=> Mlv3V2FPT0WU
YKG-1 MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwMEWwO|Eh|ryP NGDibm9USU6JRWK=
KYSE-150 NHTPcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO1XWlKSzVyPUCuNFUzOzVizszN MVHTRW5ITVJ?
HuO-3N1 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH5WoNMUUN3ME2wMlA2OjN5IN88US=> M4raS3NCVkeHUh?=
LB1047-RCC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojaTWM2OD1yLkC1Nlk3KM7:TR?= NWLObJB6W0GQR1XS
NCI-H2030 NXXKV3BKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr4S2FNUUN3ME2wMlA2PDF2IN88US=> M3ziSXNCVkeHUh?=
YH-13 NYfTOlA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\ldmlEPTB;MD6wOVczOiEQvF2= MkLlV2FPT0WU
5637 NH\PWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTUeo05UUN3ME2wMlA2PzRizszN NGjtXJRUSU6JRWK=
LOXIMVI NXfqTGdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLqTWM2OD1yLkC1PFczKM7:TR?= M3LsUnNCVkeHUh?=
GT3TKB MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[2bHlKSzVyPUCuNFU6PDJizszN NIHseHpUSU6JRWK=
TCCSUP NXrKNXE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjiTWM2OD1yLkC1PVY1KM7:TR?= MW\TRW5ITVJ?
EPLC-272H M1i3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFq4SmVKSzVyPUCuNFYzODVizszN NEOzTGpUSU6JRWK=
LU-99A M1vyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDBPHNyUUN3ME2wMlA3OjN5IN88US=> NFTWR2hUSU6JRWK=
NCI-H1755 NIHnTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPFRnJOUUN3ME2wMlA3OzRzIN88US=> MorDV2FPT0WU
KM12 NUXaTYt[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnabJhKSzVyPUCuNFY{PDhizszN MnXFV2FPT0WU
SF295 MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PBVWlEPTB;MD6wOlQ2OiEQvF2= M1fZXnNCVkeHUh?=
MZ2-MEL NYOwVYtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fTVmlEPTB;MD6wOlU2OyEQvF2= NXzYeZZSW0GQR1XS
HEC-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwME[1PFgh|ryP Mn3GV2FPT0WU
SW684 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPWTWM2OD1yLkC2OVkyKM7:TR?= NEfue4ZUSU6JRWK=
SF539 M3zFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj0eZhxUUN3ME2wMlA3PjhzIN88US=> M2HXVnNCVkeHUh?=
GMS-10 NWXxXZd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX71bnZ6UUN3ME2wMlA3Pjl7IN88US=> MVPTRW5ITVJ?
MV-4-11 MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwME[4NFMh|ryP NYnHW29DW0GQR1XS
HT-29 M1[yXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvjR45pUUN3ME2wMlA3QTF7IN88US=> MlnwV2FPT0WU
23132-87 NYWzVFZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwME[5OUDPxE1? NE\pdHhUSU6JRWK=
SW620 NHjndlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnj[JdKSzVyPUCuNFcxOjZizszN MU\TRW5ITVJ?
HCC1806 M1zMNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULZRZR5UUN3ME2wMlA4OTNzIN88US=> NWP2RZBbW0GQR1XS
Hs-578-T MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfJV2o5UUN3ME2wMlA4OjB6IN88US=> MnzaV2FPT0WU
A2058 NHjRUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMEeyNlgh|ryP MojCV2FPT0WU
MEL-HO MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\ZXZpKSzVyPUCuNFczPTVizszN NXXqOY1EW0GQR1XS
HCC2998 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlj0TWM2OD1yLkC3N|Q4KM7:TR?= NYPVV5JnW0GQR1XS
HuO9 M{juOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPHWY5KSzVyPUCuNFc2QDlizszN Mnr0V2FPT0WU
CAL-39 M4flcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwMEe3OlYh|ryP NEiwVopUSU6JRWK=
M14 NVTNZ2lTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml35TWM2OD1yLkC3PVE{KM7:TR?= NXnmOIZyW0GQR1XS
BFTC-909 MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHyxO2dKSzVyPUCuNFc6PjlizszN M2DnTXNCVkeHUh?=
TE-11 MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMEe5PVYh|ryP MXjTRW5ITVJ?
TGBC1TKB MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moi0TWM2OD1yLkC4NFQ{KM7:TR?= MULTRW5ITVJ?
L-363 M33rRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvWd|dKSzVyPUCuNFgzODZizszN NHvZVYtUSU6JRWK=
A431 Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TvWGlEPTB;MD6wPFIyKM7:TR?= MWnTRW5ITVJ?
MKN45 NXvvVoNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMEiyNVkh|ryP M3q4W3NCVkeHUh?=
HT-1080 MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7MTWM2OD1yLkC4OFM6KM7:TR?= MVHTRW5ITVJ?
OVCAR-8 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnDXGs1UUN3ME2wMlA5PjJ{IN88US=> NEPOUGhUSU6JRWK=
LCLC-97TM1 M2fkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMEi3Nlgh|ryP NF7ZUmJUSU6JRWK=
M059J M{Lmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVm1NXJvUUN3ME2wMlA6ODJ5IN88US=> NXnqV45jW0GQR1XS
SK-MEL-2 NV;Tc|h1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHmTWM2OD1yLkC5NFYh|ryP MWHTRW5ITVJ?
TE-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGCyTYJKSzVyPUCuNFkzODRizszN Mk[0V2FPT0WU
KYSE-180 MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLCTWM2OD1yLkC5NlYzKM7:TR?= M4TuZnNCVkeHUh?=
D-247MG NFnSeWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLic2w5UUN3ME2wMlA6PDV3IN88US=> M{H4WXNCVkeHUh?=
8-MG-BA MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nve2lEPTB;MD6wPVQ4OiEQvF2= MW\TRW5ITVJ?
NCI-H1792 M3ryTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO1UmlVUUN3ME2wMlA6PjF6IN88US=> Ml\EV2FPT0WU
MCF7 NFfEdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXRdHdyUUN3ME2wMlA6Pjd5IN88US=> M2rDNnNCVkeHUh?=
NCI-H2122 MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYqyV4UxUUN3ME2wMlA6PzR3IN88US=> M4WzenNCVkeHUh?=
EFO-27 NVjGNJJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrlbXo1UUN3ME2wMlA6QTl5IN88US=> MkGwV2FPT0WU
LB2241-RCC M4eyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfWTWM2OD1yLkGwNFU1KM7:TR?= M3rEXHNCVkeHUh?=
SN12C NU\aWmtrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjFb21IUUN3ME2wMlExOTB5IN88US=> Mn;4V2FPT0WU
A498 NXPVdolRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzMNohjUUN3ME2wMlExOThizszN NWLncnZnW0GQR1XS
PANC-03-27 NYXtOGY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwMUCyPFYh|ryP M2DZenNCVkeHUh?=
NCI-H1581 NFnVPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfCRZhKSzVyPUCuNVAzQSEQvF2= Ml;BV2FPT0WU
U-87-MG MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITmVZNKSzVyPUCuNVA{ODdizszN NGX1e3JUSU6JRWK=
G-401 MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr5WHNPUUN3ME2wMlExOzV|IN88US=> NVnyT2tCW0GQR1XS
SiHa NV\NfW17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW1TWM2OD1yLkGwOFg3KM7:TR?= M4XpdXNCVkeHUh?=
U251 NH7rbFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTIXZJKSzVyPUCuNVA2OjVizszN M3WxW3NCVkeHUh?=
MMAC-SF NIqwNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHZTY9KSzVyPUCuNVA2OzFizszN MYjTRW5ITVJ?
BB65-RCC NGjUO|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHUTWM2OD1yLkGwOVU1KM7:TR?= NEHXPJhUSU6JRWK=
NKM-1 NUDueFBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXY[5pKSzVyPUCuNVA3PjZizszN NUm0U3U1W0GQR1XS
HD-MY-Z MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH0b|F2UUN3ME2wMlExQDd|IN88US=> NYfJU5NSW0GQR1XS
TGBC11TKB M3;ofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHScFZKSzVyPUCuNVA6ODNizszN MkDLV2FPT0WU
COLO-679 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzxV5VwUUN3ME2wMlEyOjFzIN88US=> M4PK[nNCVkeHUh?=
TE-8 NWHQPGFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVy4N2o4UUN3ME2wMlEyOjZ2IN88US=> MXfTRW5ITVJ?
SK-MEL-28 NVLj[WNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn34TWM2OD1yLkGxN|IyKM7:TR?= Ml;5V2FPT0WU
SH-4 M1W2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fmOmlEPTB;MD6xNVM2PiEQvF2= NGO5PIVUSU6JRWK=
KALS-1 NYjpNpVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMUGzPVMh|ryP M3zVOnNCVkeHUh?=
RKO M3LRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFK1T|lKSzVyPUCuNVE4PjRizszN MWnTRW5ITVJ?
OMC-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HiOGlEPTB;MD6xNVc6PyEQvF2= NFnpcYdUSU6JRWK=
BT-549 MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LaRWlEPTB;MD6xNVc6QSEQvF2= M3L5VnNCVkeHUh?=
NCI-H28 MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvldVg2UUN3ME2wMlEyQDF5IN88US=> MoTWV2FPT0WU
RXF393 NE\TblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMUG5PFIh|ryP NF;icWVUSU6JRWK=
COLO-829 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlf1TWM2OD1yLkGyNFA2KM7:TR?= MYfTRW5ITVJ?
HMV-II NInRcWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PpdGlEPTB;MD6xNlAzKM7:TR?= M2Hs[HNCVkeHUh?=
SW1990 NUHoWJg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMUKxOVch|ryP M2rJUnNCVkeHUh?=
NCI-H1437 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPVPIcxUUN3ME2wMlEzOTV5IN88US=> Mm\mV2FPT0WU
SNB75 M1TLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMUKxOlkh|ryP NYfWXpI6W0GQR1XS
EW-3 NUTOeIl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMUK2OlEh|ryP M3yxeHNCVkeHUh?=
SAS M3PH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XwOmlEPTB;MD6xNlY6KM7:TR?= M{fK[3NCVkeHUh?=
NCI-H1666 NUPMWnZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfmTWM2OD1yLkGyO|c1KM7:TR?= MlTWV2FPT0WU
A375 NHLsfpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7K[ZNKSzVyPUCuNVI4PzhizszN MnHsV2FPT0WU
CAMA-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DBdWlEPTB;MD6xNlkzPCEQvF2= Mnu1V2FPT0WU
HuP-T4 NGewXJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXyOWZHUUN3ME2wMlEzQTR|IN88US=> MYDTRW5ITVJ?
NCI-H292 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHRVppbUUN3ME2wMlE{OTFizszN NX:wOHRSW0GQR1XS
PC-14 NVG5NIQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHwemFpUUN3ME2wMlE{OjFzIN88US=> NUDESoNZW0GQR1XS
BPH-1 M3ztNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMUO0NUDPxE1? NWHmO4d7W0GQR1XS
GAK MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknWTWM2OD1yLkGzOVY4KM7:TR?= NGXSW|dUSU6JRWK=
VMRC-RCZ NIn1TGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW2R2pKSzVyPUCuNVM4PjJizszN MUXTRW5ITVJ?
SK-MEL-24 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnOO|llUUN3ME2wMlE{QDdizszN MYXTRW5ITVJ?
LB831-BLC M1Tid2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HESGlEPTB;MD6xN|g5OyEQvF2= MlfNV2FPT0WU
NCI-H2452 M2DEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHnTWM2OD1yLkGzPVU3KM7:TR?= MnjaV2FPT0WU
RT-112 MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nlPWlEPTB;MD6xOFA{PSEQvF2= MknPV2FPT0WU
GP5d MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMUSxNFQh|ryP MnKwV2FPT0WU
LC-2-ad M4HHWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX0TWM2OD1yLkG0NVIyKM7:TR?= NXf5O5kyW0GQR1XS
MPP-89 NWi3OGIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C2XmlEPTB;MD6xOFEzPSEQvF2= NVvLNGpwW0GQR1XS
NUGC-3 M3LUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMUS0O|gh|ryP NGTiR|VUSU6JRWK=
GI-1 Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMUS1OVgh|ryP M33M[3NCVkeHUh?=
HCC1419 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTwfGlRUUN3ME2wMlE1PTd4IN88US=> NX\qNGdxW0GQR1XS
SW1573 NYOzPHROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwMUS3OVgh|ryP M3PoU3NCVkeHUh?=
NCI-H2347 NX35RYFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT6PYRGUUN3ME2wMlE1QDN7IN88US=> NXnDdWZCW0GQR1XS
Mewo NYW5bmNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnXfoE{UUN3ME2wMlE1QDh7IN88US=> M1[1SnNCVkeHUh?=
639-V M13aR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPMTWM2OD1yLkG1NFE{KM7:TR?= NHzLT3RUSU6JRWK=
AsPC-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP3SWJKSzVyPUCuNVUzOjVizszN M{K1NnNCVkeHUh?=
NCI-H1648 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwMUWyN|Ih|ryP NFrvb|JUSU6JRWK=
786-0 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTvSmJKSzVyPUCuNVU{QDFizszN MUPTRW5ITVJ?
ETK-1 NFfRboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMUW5JO69VQ>? NGXtSJpUSU6JRWK=
BxPC-3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPkTWM2OD1yLkG1PVY3KM7:TR?= NXzNRXhkW0GQR1XS
CAL-62 NHri[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17YVmlEPTB;MD6xOlE3QSEQvF2= MXvTRW5ITVJ?
HCC1937 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PZNGlEPTB;MD6xOlI4PSEQvF2= MV3TRW5ITVJ?
NCI-H1299 MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMU[yPFUh|ryP NVrxSI5nW0GQR1XS
SW1088 MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPhWnhKSzVyPUCuNVY1OTNizszN MoHGV2FPT0WU
FTC-133 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLzSIp5UUN3ME2wMlE3PTRizszN M4X1[HNCVkeHUh?=
OC-314 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm1TWM2OD1yLkG2Olkh|ryP NF3CflVUSU6JRWK=
SCC-9 MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInVNoJKSzVyPUCuNVY4OTZizszN MWLTRW5ITVJ?
HT-1376 NXTEbWo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMU[5N|Yh|ryP NXnsRYY6W0GQR1XS
U-2-OS MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml6zTWM2OD1yLkG3NVc{KM7:TR?= MYLTRW5ITVJ?
COLO-824 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PTS2lEPTB;MD6xO|I6PCEQvF2= MkHaV2FPT0WU
BB30-HNC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMUezN{DPxE1? MVHTRW5ITVJ?
NCI-H2087 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzFTWM2OD1yLkG3N|Y5KM7:TR?= Mk\IV2FPT0WU
NCI-H2170 M13Ubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFT0[5JKSzVyPUCuNVc2OzZizszN NHnLeVlUSU6JRWK=
SK-OV-3 NEW2eJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHLTWM2OD1yLkG3OVcyKM7:TR?= MnLuV2FPT0WU
MZ7-mel M3vudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVP0XZR3UUN3ME2wMlE4PjR7IN88US=> NGm2bYhUSU6JRWK=
NCI-H650 NInPe5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMUe2PFIh|ryP M2XMO3NCVkeHUh?=
KOSC-2 M2nncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3y0ZmlEPTB;MD6xO|c{PCEQvF2= NVLH[5hFW0GQR1XS
SCC-4 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwMUe3O|ch|ryP M335THNCVkeHUh?=
MDA-MB-157 NYnSNWo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\EfWt2UUN3ME2wMlE5ODh{IN88US=> NGHCU45USU6JRWK=
KYSE-520 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTyTWM2OD1yLkG4NkDPxE1? NFjSO4dUSU6JRWK=
LK-2 NF32ZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmSwTWM2OD1yLkG4N|A{KM7:TR?= NFHuOlBUSU6JRWK=
KNS-81-FD NUftNYVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTQdWpKSzVyPUCuNVg{QTRizszN MUPTRW5ITVJ?
IGROV-1 MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjQOlVKSzVyPUCuNVg1PDNizszN MVzTRW5ITVJ?
DEL MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PNTmlEPTB;MD6xPFQ2KM7:TR?= MlfMV2FPT0WU
NCI-H1395 M2nIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMUi2PFIh|ryP NGjpWJFUSU6JRWK=
JEG-3 NXK4W3lyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\yTHFKSzVyPUCuNVg4ODVizszN M2\RSnNCVkeHUh?=
BCPAP NGjtdHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnleYQ5UUN3ME2wMlE5QDd{IN88US=> NXnPcGZ6W0GQR1XS
CAL-27 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMUmwNlIh|ryP M3rBeHNCVkeHUh?=
RD MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG5XHc{UUN3ME2wMlE6OTF|IN88US=> M1TvbXNCVkeHUh?=
RVH-421 NX3qU4hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwMUmxNVYh|ryP NEDjNFRUSU6JRWK=
Capan-2 NYHHRotpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInyPYNKSzVyPUCuNVkzPTZizszN NI\sNm9USU6JRWK=
COLO-680N MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMUmzOlQh|ryP NH;XblZUSU6JRWK=
NCI-H1650 NHPpO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXT0blRZUUN3ME2wMlIxODV5IN88US=> M4\JWXNCVkeHUh?=
SBC-5 NHviRmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr3cWtKSzVyPUCuNlAyOThizszN NWXldmYzW0GQR1XS
U031 M1fS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17BfmlEPTB;MD6yNFU1PyEQvF2= MVzTRW5ITVJ?
S-117 Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnhV3RXUUN3ME2wMlIxPTZ2IN88US=> M{PBd3NCVkeHUh?=
DoTc2-4510 MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfrRoZKSzVyPUCuNlA4PjlizszN M3P3N3NCVkeHUh?=
AM-38 NX[yXIdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{GyZ2lEPTB;MD6yNFg1QCEQvF2= MkLXV2FPT0WU
A172 NHvGVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLmTWM2OD1yLkKxNFIzKM7:TR?= NHu5cZJUSU6JRWK=
HPAF-II M2DyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3PN|RCUUN3ME2wMlIyOjZ2IN88US=> NIfOWY1USU6JRWK=
769-P NY\QbnRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[zW|dKSzVyPUCuNlEzQCEQvF2= NIX1Z3BUSU6JRWK=
MFE-280 NXPzXYZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMkGyPVgh|ryP M17uRnNCVkeHUh?=
TE-9 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LsOmlEPTB;MD6yNVc5PiEQvF2= NF;oRpFUSU6JRWK=
C2BBe1 NIiwUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMkKxPUDPxE1? MkLqV2FPT0WU
EoL-1-cell MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIOweoVKSzVyPUCuNlIzODNizszN M3\hZ3NCVkeHUh?=
G-361 MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTKbXBnUUN3ME2wMlIzPjh{IN88US=> NUXKO2VFW0GQR1XS
KYSE-270 M{P0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPQTWM2OD1yLkKzNFg1KM7:TR?= MoezV2FPT0WU
TK10 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMkOxNVch|ryP NYSwXm1yW0GQR1XS
ML-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwMkOxNVkh|ryP M4fGbXNCVkeHUh?=
MHH-ES-1 NUm5UpRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr4cZlKSzVyPUCuNlM3QDFizszN NE\Vd4JUSU6JRWK=
BHY M1PZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHny[otKSzVyPUCuNlM3QTFizszN M{HoT3NCVkeHUh?=
LS-513 NXHzWZBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMkO5OlEh|ryP M4C3[nNCVkeHUh?=
COLO-678 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLlfng1UUN3ME2wMlI1ODR2IN88US=> M1nueXNCVkeHUh?=
NCI-H747 MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMkSxOlkh|ryP NGCxeY5USU6JRWK=
K5 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMkSzPEDPxE1? NW\ON5RsW0GQR1XS
OS-RC-2 M4\qdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHOTWM2OD1yLkK0OVA6KM7:TR?= NEH0VJdUSU6JRWK=
KINGS-1 M1z3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMkS1Nlkh|ryP MYDTRW5ITVJ?
SCC-25 NFfiR41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHPTWM2OD1yLkK0OVY{KM7:TR?= NHfzOGlUSU6JRWK=
CAPAN-1 NUTMOlVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLkb2FKSzVyPUCuNlQ4QDNizszN NIDBdGxUSU6JRWK=
ESS-1 NXz6fmZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVuzdVNQUUN3ME2wMlI1QDB3IN88US=> NFrLbldUSU6JRWK=
TE-6 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{W3NWlEPTB;MD6yOVc2KM7:TR?= MkThV2FPT0WU
LB2518-MEL Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmezTWM2OD1yLkK1O|c4KM7:TR?= NFLW[3hUSU6JRWK=
COLO-800 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;WXZB{UUN3ME2wMlI2QDF{IN88US=> NXPIcWxzW0GQR1XS
LU-134-A MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMk[xN|Yh|ryP MnLNV2FPT0WU
NCI-H1155 NX7BUWFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3e2UWlEPTB;MD6yOlE3OiEQvF2= NEPGPHRUSU6JRWK=
MFM-223 Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\YTWM2OD1yLkK2N|Y{KM7:TR?= M3GzdnNCVkeHUh?=
HTC-C3 NETQdZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nqS2lEPTB;MD6yOlUxPiEQvF2= MW\TRW5ITVJ?
HCT-116 NYKzUFk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYO2cpY5UUN3ME2wMlI3PTl7IN88US=> NHPrd3ZUSU6JRWK=
Ca-Ski NGn4TlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfvTmVHUUN3ME2wMlI3Pjd6IN88US=> NX2yV2RoW0GQR1XS
SBC-1 NVW2SlBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPzPWdvUUN3ME2wMlI3PzR{IN88US=> MULTRW5ITVJ?
NB69 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rGdWlEPTB;MD6yO|A5PyEQvF2= Mke3V2FPT0WU
J82 NGm3bW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{ntXGlEPTB;MD6yO|I3PSEQvF2= NWTGdmJSW0GQR1XS
U-118-MG NGLxeFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDkTWM2OD1yLkK3OVc6KM7:TR?= M4XqTnNCVkeHUh?=
NCI-H1355 NHTWOWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NICwcFhKSzVyPUCuNlgxPzRizszN M2PabHNCVkeHUh?=
NCI-H1048 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfFXHVKSzVyPUCuNlg6PTZizszN NYeyOpFbW0GQR1XS
SW954 MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3G[FRrUUN3ME2wMlI6OjJ5IN88US=> MnKxV2FPT0WU
NMC-G1 MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXRVXJxUUN3ME2wMlI6Ojd5IN88US=> NGfnXGFUSU6JRWK=
SW1710 NF\HVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHZUYNUUUN3ME2wMlI6PDl2IN88US=> Mm\vV2FPT0WU
KY821 MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\RTWM2OD1yLkK5PFczKM7:TR?= MX;TRW5ITVJ?
HCC38 NH3LeItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DueWlEPTB;MD6zNFA4QCEQvF2= M1K3fHNCVkeHUh?=
NCI-SNU-5 NGW5NGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[3cG1KSzVyPUCuN|A2PCEQvF2= M2DENHNCVkeHUh?=
ES8 MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrTVnpKSzVyPUCuN|A4QDRizszN MnLyV2FPT0WU
COLO-792 M{f0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHxbFVKSzVyPUCuN|EzPTFizszN MVnTRW5ITVJ?
BFTC-905 Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVn4WlRVUUN3ME2wMlMyPTJzIN88US=> M{\2ZnNCVkeHUh?=
ChaGo-K-1 MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwM{G3NVUh|ryP MmHzV2FPT0WU
Daoy MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwM{G3NlMh|ryP M37rUXNCVkeHUh?=
SJSA-1 NUPqN3YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXLPIlCUUN3ME2wMlMyQDR5IN88US=> NVm3V4JSW0GQR1XS
KNS-62 NXv4UW5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTQR4FKSzVyPUCuN|IxQDhizszN M1PxUnNCVkeHUh?=
CAKI-1 NF\aVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\jTWM2OD1yLkOyNVEyKM7:TR?= NFi4W3JUSU6JRWK=
UACC-62 NEXTb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfhUW9KSzVyPUCuN|IzOjdizszN M2P5bXNCVkeHUh?=
HuCCT1 MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTFTWM2OD1yLkOyNlg{KM7:TR?= NHL2OmxUSU6JRWK=
CTB-1 Mn3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwM{K3OVMh|ryP M1jGd3NCVkeHUh?=
NTERA-S-cl-D1 M{DWNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;CN2lEPTB;MD6zNlg{PiEQvF2= MWDTRW5ITVJ?
T-24 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\kb2lEPTB;MD6zN|E2QSEQvF2= NIGy[JBUSU6JRWK=
KYSE-70 NF3FSINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTxfotXUUN3ME2wMlM{Ojh|IN88US=> MljzV2FPT0WU
SW626 M4\uXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojzTWM2OD1yLkOzOVMzKM7:TR?= M1TRTnNCVkeHUh?=
LB996-RCC Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwM{O2NVkh|ryP M17Td3NCVkeHUh?=
DMS-273 NXfqPHAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon3TWM2OD1yLkOzPVE3KM7:TR?= NGXrdYNUSU6JRWK=
SW1783 NFnrPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzw[ml6UUN3ME2wMlM{QTl5IN88US=> MlTZV2FPT0WU
KU812 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfJbYlkUUN3ME2wMlM1ODN6IN88US=> NVzvToVLW0GQR1XS
HSC-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:1[GlEPTB;MD6zOFA2OyEQvF2= MW\TRW5ITVJ?
A3-KAW M3j1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHPTYpKSzVyPUCuN|QyPjJizszN NXzH[2J[W0GQR1XS
COLO-684 NH7tcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjYTWM2OD1yLkO0OVAyKM7:TR?= NX3oOGZ5W0GQR1XS
NCI-H2405 NFz3VZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwM{S2N|Eh|ryP Mn2yV2FPT0WU
NCI-H2228 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q5ZWlEPTB;MD6zOVM2PyEQvF2= NXTtVY1GW0GQR1XS
NB13 M3jndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v2TGlEPTB;MD6zOlgzQSEQvF2= NYnrOWwxW0GQR1XS
no-11 NEHGSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL5O2JLUUN3ME2wMlM3QTVizszN Mke3V2FPT0WU
DK-MG MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjyTWM2OD1yLkO3NVg5KM7:TR?= M1y5[3NCVkeHUh?=
NBsusSR NIf6VmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTKTWM2OD1yLkO3Nlg2KM7:TR?= NFvObohUSU6JRWK=
KP-N-YS MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLsPVRKSzVyPUCuN|c1PjNizszN Mo[xV2FPT0WU
CFPAC-1 MojrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjlSGcxUUN3ME2wMlM4PTF6IN88US=> NFT5S2lUSU6JRWK=
KARPAS-45 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nXcmlEPTB;MD6zO|g3OiEQvF2= NIPUO5pUSU6JRWK=
NCI-H1793 NIPuZYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnVdI02UUN3ME2wMlM5PTFizszN M12zTHNCVkeHUh?=
HCE-T NF3KfnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\4PWN2UUN3ME2wMlM5PjB|IN88US=> MYnTRW5ITVJ?
NCI-H520 NVrpXYs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nhWmlEPTB;MD6zPFcxOyEQvF2= NF;5cGVUSU6JRWK=
HCC2157 M{\CSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7rOVhKSzVyPUCuN|g4QDFizszN MXvTRW5ITVJ?
EW-18 M1LLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13jRmlEPTB;MD6zPFk1OSEQvF2= MWLTRW5ITVJ?
RO82-W-1 NFHOfnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwM{m2PVkh|ryP NEHrSXBUSU6JRWK=
HuP-T3 M2LPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\IS2lEPTB;MD60NFE1OyEQvF2= NF3yZm1USU6JRWK=
PANC-10-05 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjXPWlKSzVyPUCuOFEyPyEQvF2= MX;TRW5ITVJ?
NCI-H1703 M4TRTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3z3OmlEPTB;MD60NVQ1PiEQvF2= MYrTRW5ITVJ?
TE-10 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwNEG0OFch|ryP NFHYPJZUSU6JRWK=
HOS M3\lTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTsNYRKSzVyPUCuOFE3QDJizszN MVLTRW5ITVJ?
LN-405 NVLEZ2NVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;vXWlEPTB;MD60NVY5PyEQvF2= M4ixNnNCVkeHUh?=
A427 M13YNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwNEG5PFEh|ryP MnniV2FPT0WU
CAL-12T MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwNEK3PEDPxE1? NWrtfVVsW0GQR1XS
SW756 M2\SWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXYR45KSzVyPUCuOFQyQDNizszN MnH3V2FPT0WU
YAPC M17ORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwNEWwPEDPxE1? NYrDTYpjW0GQR1XS
GOTO MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwNEWxOkDPxE1? NF7NUlFUSU6JRWK=
C3A NWTIXGE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFOx[YxKSzVyPUCuOFU1OzdizszN MlvKV2FPT0WU
UM-UC-3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPuTWM2OD1yLkS1OFch|ryP M1jCVXNCVkeHUh?=
NCI-H1573 NH;hPZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW5OZlKSzVyPUCuOFU2PjlizszN NG\I[pZUSU6JRWK=
LS-411N MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXqcm9OUUN3ME2wMlQ3PTJ5IN88US=> M2P5NHNCVkeHUh?=
COR-L23 Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwNE[3OlQh|ryP NVXvbYZtW0GQR1XS
HCE-4 MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTNd5RrUUN3ME2wMlQ4PDR4IN88US=> NVHnUpcyW0GQR1XS
NCI-H2291 NGqy[mFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwNEe4PVYh|ryP Mn70V2FPT0WU
A101D MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\HZmlEPTB;MD60PFA2OyEQvF2= MkHOV2FPT0WU
HT-3 MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWKyTJU3UUN3ME2wMlQ5OjF5IN88US=> NIjMT2NUSU6JRWK=
HOP-62 NHrkVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwNEm4OlUh|ryP NGWyWlJUSU6JRWK=
PC-3 MkDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ewTGlEPTB;MD61NVUxPyEQvF2= MXnTRW5ITVJ?
CTV-1 NWXBeJdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rtRmlEPTB;MD61NlY3QSEQvF2= MV7TRW5ITVJ?
PANC-08-13 M1S0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1uxTmlEPTB;MD61N|E4PyEQvF2= NUfsbWZ[W0GQR1XS
CAL-120 M{G3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LI[mlEPTB;MD61N|M6QSEQvF2= MorXV2FPT0WU
UMC-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLFTWM2OD1yLkW1NlM1KM7:TR?= MYXTRW5ITVJ?
MSTO-211H NWXxUFlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4q5WGlEPTB;MD61OVc3OiEQvF2= NUnaRmpLW0GQR1XS
NCI-H2126 NXjqTnBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofZTWM2OD1yLkW2PFE2KM7:TR?= M3nNdXNCVkeHUh?=
SNU-C2B M1XlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD6bHJKSzVyPUCuOVc6PzdizszN MUnTRW5ITVJ?
DBTRG-05MG NXfYblhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nWXGlEPTB;MD61PFA2OyEQvF2= NFzYclFUSU6JRWK=
MKN1 NX;3boI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlyxTWM2OD1yLkW4O|g{KM7:TR?= NIPLSFRUSU6JRWK=
ES3 NX2yZWRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jWb2lEPTB;MD61PVEzPCEQvF2= M4r0WHNCVkeHUh?=
OVCAR-3 NUfjPJlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlqwTWM2OD1yLkW5N|QyKM7:TR?= M{LtVHNCVkeHUh?=
ACHN M3n3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLjTWM2OD1yLk[wOVY6KM7:TR?= NYraVIZKW0GQR1XS
SW872 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\BUGlEPTB;MD62NFc3OyEQvF2= NFXhcVdUSU6JRWK=
CP66-MEL M3jr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETpNY9KSzVyPUCuOlA6PjlizszN MWXTRW5ITVJ?
NCI-H661 NXTQbVk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXWSpA6UUN3ME2wMlYyOTB2IN88US=> NVLDWmZ2W0GQR1XS
UACC-893 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwNkO2PFEh|ryP M{DOPHNCVkeHUh?=
JVM-3 M3nRVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLoO|RKSzVyPUCuOlM5ODRizszN NFTQfWNUSU6JRWK=
SF268 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LFOmlEPTB;MD62OFM1QSEQvF2= NYLRdIxyW0GQR1XS
OCI-AML2 Mn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfNTWM2OD1yLk[1N|k4KM7:TR?= MmDwV2FPT0WU
RPMI-8226 NEO2[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjHUpduUUN3ME2wMlY3OzJ|IN88US=> NFrnZ49USU6JRWK=
MKN28 M2js[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3WyWGlEPTB;MD62OlYzPCEQvF2= M1v4dHNCVkeHUh?=
MDA-MB-453 NUi1[ZBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwNkexPEDPxE1? NE\FSWVUSU6JRWK=
BV-173 M1XaPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\MWJRKSzVyPUCuOlg3PzlizszN Mkm0V2FPT0WU
NCI-H358 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwNki3NlYh|ryP MkXWV2FPT0WU
NCI-H1651 NUmzV|VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm0TWM2OD1yLkeg{txO MWfTRW5ITVJ?
MDA-MB-415 NYrDW4t5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwN{C4Nlkh|ryP NXr5VpRqW0GQR1XS
8305C Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjLWpNKSzVyPUCuO|I1QThizszN NHrHVYtUSU6JRWK=
EFM-19 M1zx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXBOXVKSzVyPUCuO|M3PzFizszN M3j6e3NCVkeHUh?=
RERF-LC-MS NYTL[3JYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwN{S2NVMh|ryP NVr4UWtLW0GQR1XS
A388 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITHXm9KSzVyPUCuO|Y1PjdizszN MWnTRW5ITVJ?
GI-ME-N MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rESmlEPTB;MD63O|I{PSEQvF2= MXPTRW5ITVJ?
IGR-1 Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPRbJdKSzVyPUCuO|kxPDNizszN NVLSZnh[W0GQR1XS
LNCaP-Clone-FGC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTDTWM2OD1yLkiwNFA1KM7:TR?= MVTTRW5ITVJ?
SK-MEL-3 NFTOVpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHXWZo4UUN3ME2wMlgyPTB6IN88US=> MmTFV2FPT0WU
UACC-257 Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDv[41KSzVyPUCuPFIzOzFizszN M1L0NHNCVkeHUh?=
OE33 NGjM[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;nTWM2OD1yLki1NVAyKM7:TR?= M4LWenNCVkeHUh?=
QIMR-WIL NV7hWVRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv0TWM2OD1yLki1NVQyKM7:TR?= MYDTRW5ITVJ?
NCI-H2009 NH\VVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXCUllKSzVyPUCuPFU{OTFizszN M{HhZnNCVkeHUh?=
NCI-H522 NITMdlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Cy[mlEPTB;MD64O|c5OyEQvF2= NW\FbFUzW0GQR1XS
Saos-2 MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXizc2l1UUN3ME2wMlg4QDdzIN88US=> NUfjbodKW0GQR1XS
NB17 NIizNoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DVVmlEPTB;MD64PFAzPSEQvF2= MVrTRW5ITVJ?
D-392MG MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fFSGlEPTB;MD64PVM2PiEQvF2= Mn3XV2FPT0WU
SHP-77 MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\qVotKSzVyPUCuPVA1QDVizszN NILTdY5USU6JRWK=
SK-MEL-30 NIG4XplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\DWZd2UUN3ME2wMlkyOTh3IN88US=> MnS1V2FPT0WU
GCIY NFrid|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XsW2lEPTB;MD65NVg1OyEQvF2= NGnNTVJUSU6JRWK=
HCC70 NUn1c2pwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwOUKwOVkh|ryP M{LDNHNCVkeHUh?=
LU-65 M1;v[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwOUK1PVEh|ryP NE\3d|RUSU6JRWK=
NCI-H1563 NF3JcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwOUS4OlUh|ryP NILMS29USU6JRWK=
KURAMOCHI NYjlVJM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7kR4dKSzVyPUCuPVUyQTJizszN MWDTRW5ITVJ?
PA-1 MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf5[G9tUUN3ME2wMlk2PDJ2IN88US=> MXLTRW5ITVJ?
NOS-1 NUntOGJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm2TVZKSzVyPUCuPVc1QDlizszN NVnjZoF3W0GQR1XS
NCI-H69 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TCUmlEPTB;MD65O|Y{PCEQvF2= MnvGV2FPT0WU
KYSE-450 NWTGOmJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7vOIVKSzVyPUCuPVg3OjZizszN NU\jVFJ6W0GQR1XS
8505C NVfwSpQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTDNmt[UUN3ME2wMlk6QTh{IN88US=> MlziV2FPT0WU
TGBC24TKB MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTFwMECwPFQh|ryP M37MXHNCVkeHUh?=
PFSK-1 NVq2WoFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFwMEG0Nlgh|ryP NHTNN5JUSU6JRWK=
EKVX M1LoWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPlTWM2OD1zLkCzNVIyKM7:TR?= NGDkc2dUSU6JRWK=
RCM-1 NIm1SIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XPNmlEPTB;MT6wOVUxPyEQvF2= NXfiVXRFW0GQR1XS
SW900 M2\4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rrTWlEPTB;MT6wO|g{KM7:TR?= NYmyVW9oW0GQR1XS
D-542MG MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;vTWM2OD1zLkC3PFU2KM7:TR?= MUHTRW5ITVJ?
SK-PN-DW M12yNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFwMUCwOVYh|ryP NH7XUpNUSU6JRWK=
NCI-H727 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3H1cGlEPTB;MT6xNFE2PCEQvF2= MVrTRW5ITVJ?
SW837 NX7k[GxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTDTWM2OD1zLkGwPVU1KM7:TR?= NXfpfnZHW0GQR1XS
BT-20 M{W2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjwTWM2OD1zLkGxNlA1KM7:TR?= MlLOV2FPT0WU
RH-18 MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFwMUOxNFMh|ryP M{e1ZnNCVkeHUh?=
TE-12 NVXTPFVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3BcYdKSzVyPUGuNVM{OzNizszN MmfHV2FPT0WU
NB10 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXuRplNUUN3ME2xMlE{OzR2IN88US=> NXHnc|dRW0GQR1XS
AU565 Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXna[5pIUUN3ME2xMlE2QTd|IN88US=> MXjTRW5ITVJ?
OAW-42 NF7tcXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjvRXdKSzVyPUGuNVg{ODZizszN NWrWU25uW0GQR1XS
DJM-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rPXmlEPTB;MT6xPVg5OSEQvF2= NWPBTFhjW0GQR1XS
HH Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnLT2t[UUN3ME2xMlI{QDNzIN88US=> Mn6zV2FPT0WU
LAMA-84 NWXVfpJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFwMkezPVQh|ryP MnLiV2FPT0WU
KNS-42 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j4OGlEPTB;MT6zNFI6PiEQvF2= MUDTRW5ITVJ?
NCI-H2052 MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD2U4syUUN3ME2xMlMxPTB5IN88US=> Mn;BV2FPT0WU
MLMA NUfLPJdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTFwM{K0NFch|ryP MYDTRW5ITVJ?
NB12 NULkT3c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS4OJNKSzVyPUGuN|U3OzZizszN MXjTRW5ITVJ?
NCI-H1838 MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjVTWM2OD1zLkO2N|A3KM7:TR?= MYXTRW5ITVJ?
NCI-H526 MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzCTWM2OD1zLkO3PFU{KM7:TR?= NEfHSldUSU6JRWK=
LS-123 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwM{mwPVQh|ryP NV3F[VZjW0GQR1XS
HDLM-2 NEDYcVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DwVGlEPTB;MT6zPVI4OSEQvF2= M1POfXNCVkeHUh?=
MC-IXC Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTFwNEKzO|Eh|ryP NWCxVZk5W0GQR1XS
HCT-15 Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLCTWM2OD1zLkSzNFY5KM7:TR?= M2HTdXNCVkeHUh?=
NCI-H596 M1LufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXicJBKSzVyPUGuOFUxPjFizszN NF[3SoZUSU6JRWK=
ZR-75-30 NH3mfFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TNZWlEPTB;MT60O|A5OiEQvF2= NHrMV2tUSU6JRWK=
A704 M1\qdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2GwTWlEPTB;MT62OlU3OyEQvF2= Mnq4V2FPT0WU
OVCAR-4 NFPBfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7xO5VpUUN3ME2xMlY6PjB5IN88US=> M{LwTHNCVkeHUh?=
SW1417 Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPJRXREUUN3ME2xMlczQDR7IN88US=> M3\YPXNCVkeHUh?=
CAS-1 NHnCNFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;Y[mlEPTB;MT63N|k{PiEQvF2= MnzxV2FPT0WU
IST-SL1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\nTWM2OD1zLke5O|U6KM7:TR?= Mn73V2FPT0WU
A253 M4X2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrz[pNKSzVyPUGuPFIzOzlizszN MlHxV2FPT0WU
EW-16 NYTTT2ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIntRoNKSzVyPUGuPFI5PzVizszN NUfsfJY5W0GQR1XS
SK-NEP-1 NUOycnVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTOdmhKSzVyPUGuPFY6QDhizszN MljKV2FPT0WU
NCI-H226 NF\nZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFwOEmzOVkh|ryP MmD3V2FPT0WU
HOP-92 MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPJOWdJUUN3ME2xMlk3ODl7IN88US=> MoroV2FPT0WU
NCI-H441 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjZTWM2OD1{LkCyN|M4KM7:TR?= NVL5ZYNFW0GQR1XS
LU-139 NFPUSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJwMEOxNVQh|ryP MXnTRW5ITVJ?
SJRH30 Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\RZXFrUUN3ME2yMlA1OjV|IN88US=> M{\6UXNCVkeHUh?=
MG-63 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3EeoFDUUN3ME2yMlE1OTFzIN88US=> MkXxV2FPT0WU
NH-12 NV2yfVIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\ycFRKSzVyPUKuNVUxODZizszN MUfTRW5ITVJ?
NB7 NIrobo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJwMUm2O|Mh|ryP NIr5RVVUSU6JRWK=
LB771-HNC MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEj0dmtKSzVyPUKuNlA2QTVizszN NEXXUINUSU6JRWK=
HCC1569 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJwMkS1PFMh|ryP NHm1S45USU6JRWK=
D-283MED MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\hV2lEPTB;Mj6yOFc5OiEQvF2= M4H4SXNCVkeHUh?=
J-RT3-T3-5 NILsTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjSfFZKSzVyPUKuNlU{PTFizszN MnzEV2FPT0WU
ATN-1 M{XB[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7YVXVPUUN3ME2yMlM{ODh{IN88US=> M4LMUHNCVkeHUh?=
HCC1954 NIXjN4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrpTWM2OD1{LkO0OFA5KM7:TR?= MlLUV2FPT0WU
SCC-15 Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXITWM2OD1{LkO5N|EzKM7:TR?= MXnTRW5ITVJ?
COLO-668 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJwNEOyJO69VQ>? NYnzUHhJW0GQR1XS
LB373-MEL-D MmDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzUfGRKSzVyPUKuOVQ3PzdizszN MXTTRW5ITVJ?
no-10 NYr3Zld7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTSdnRRUUN3ME2yMlU1QTR5IN88US=> NWn0O2VSW0GQR1XS
HT-1197 NUPp[mFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJwNkOxPFgh|ryP MYXTRW5ITVJ?
DU-145 NIfZS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3noRmlEPTB;Mj63PVE3OiEQvF2= NIfFW4NUSU6JRWK=
SK-N-AS NEXEUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJwOES2PVIh|ryP Mn\vV2FPT0WU
MOLT-4 NXPhRXNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33yU2lEPTB;Mj64OVMzOiEQvF2= MWDTRW5ITVJ?
EW-22 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJwOUK4OFEh|ryP MlG2V2FPT0WU
DB NHLacFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlToTWM2OD1{Lkm3O|U6KM7:TR?= M4HaWXNCVkeHUh?=
HL-60 M4LkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYn5UGw3UUN3ME2zMlA1Ozd4IN88US=> NIXDOZpUSU6JRWK=
SK-N-DZ NUC0coJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTNwMEWwO|Uh|ryP MWPTRW5ITVJ?
NY M3LmcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTNwMEi1OFIh|ryP MmGzV2FPT0WU
T47D M{Doemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIKxcolKSzVyPUOuNVA2PThizszN MlrGV2FPT0WU
NCI-H2029 M1HmPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTNwMkK0O|ch|ryP MmnBV2FPT0WU
KARPAS-299 M2fadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HnT2lEPTB;Mz6yOlAzPyEQvF2= MWXTRW5ITVJ?
KM-H2 Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W2T2lEPTB;Mz6zNFY5KM7:TR?= NYLpeXlqW0GQR1XS
CHP-134 NHT4R3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTNwNEezPUDPxE1? M3XXTHNCVkeHUh?=
22RV1 M2XDW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTNwNEmxOlgh|ryP MmPBV2FPT0WU
NB5 NVW2ZYdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnz5TWM2OD1|LkWwOlg6KM7:TR?= MVrTRW5ITVJ?
CW-2 NVzDdGtJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTNwNUWzNVQh|ryP NXnOTmg5W0GQR1XS
EFO-21 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTNwNU[5OEDPxE1? NV7TdVh7W0GQR1XS
HuH-7 Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTNwNUi0NVQh|ryP NUTOXY5CW0GQR1XS
ALL-PO NUTLRVlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LTPGlEPTB;Mz62NlM{PSEQvF2= MV3TRW5ITVJ?
EM-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7vV5FNUUN3ME2zMlY6ODFzIN88US=> MVjTRW5ITVJ?
KLE NHnHdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjURlZKSzVyPUOuO|MxOjlizszN MoTyV2FPT0WU
NEC8 NVzqWVNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTNwOUG4NFgh|ryP NFvLTlVUSU6JRWK=
KP-N-YN NHzy[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrBRlRKSzVyPUOuPVM1PzZizszN MlW4V2FPT0WU
SK-MEL-1 NYnCbW5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfiTWM2OD12LkCzOVE5KM7:TR?= NFGwSJFUSU6JRWK=
CAL-54 M2TuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInScXVKSzVyPUSuNFU6OSEQvF2= MYTTRW5ITVJ?
MS-1 Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnW2TWM2OD12LkG2NVU2KM7:TR?= NXX5c3FqW0GQR1XS
NCI-H209 NIGzdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rJUGlEPTB;ND6yPVk6QSEQvF2= M{TzPXNCVkeHUh?=
NOMO-1 NYL3RW9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjZS5ZCUUN3ME20MlMzOTNzIN88US=> MnzsV2FPT0WU
RPMI-2650 NVflTItLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXYdoV6UUN3ME20MlM3OzJ5IN88US=> M322Z3NCVkeHUh?=
NCI-H810 NFjLcYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTRwM{m3N|Yh|ryP M1nWXXNCVkeHUh?=
Ca9-22 M2\pbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvFTWM2OD12LkS1OlkyKM7:TR?= NIHXR3hUSU6JRWK=
ES4 NEX4XGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTRwNEewPVUh|ryP NGXyWZRUSU6JRWK=
ES6 NEDiNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnraTWM2OD12LkS5OlU4KM7:TR?= M{i3bXNCVkeHUh?=
DMS-114 NGHZT|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWqybZRQUUN3ME20MlU1PjlzIN88US=> MXnTRW5ITVJ?
ONS-76 MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33pN2lEPTB;ND61O|k2KM7:TR?= M2e2UXNCVkeHUh?=
K-562 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\GR|VKSzVyPUSuO|M5OTRizszN NUXkcmRwW0GQR1XS
MHH-NB-11 NVnMbXgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTRwN{W0OlEh|ryP NFvD[lFUSU6JRWK=
Calu-3 M32zbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LZTWlEPTB;ND63PFU1QCEQvF2= NVj3elJ6W0GQR1XS
HT55 MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfXTWM2OD12Lki0OVQ2KM7:TR?= MnK0V2FPT0WU
SK-N-FI MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH6zc5VKSzVyPUSuPFUxODlizszN MXHTRW5ITVJ?
ES1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHwU3ZtUUN3ME20Mlg3ODV5IN88US=> NGCxT|NUSU6JRWK=
SF126 NIm0TFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnq2TWM2OD12LkmzNVg1KM7:TR?= MVjTRW5ITVJ?
ES5 M4[zSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPJTWM2OD13LkGyOFI4KM7:TR?= NFTBeIVUSU6JRWK=
LoVo NEjXfldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1v0c2lEPTB;NT6xOVg4OSEQvF2= M{nVRXNCVkeHUh?=
SNU-387 NVP4[VBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTVwM{KzN|kh|ryP M3znNnNCVkeHUh?=
C8166 NGKybIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;VfG1KSzVyPUWuN|Y{OzlizszN NInwXI1USU6JRWK=
LS-1034 Mmn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfjb4JKSzVyPUWuOFI{ODdizszN M2q5OXNCVkeHUh?=
GR-ST Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP5TWM2OD13LkWyNlAyKM7:TR?= NF;jc2pUSU6JRWK=
NCI-H1092 M{LTdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;0XYFKSzVyPUWuO|I5PDNizszN NV31ZYVFW0GQR1XS
647-V M4DubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fJTWlEPTB;NT63OFcxPiEQvF2= M1;GRXNCVkeHUh?=
EW-13 M362PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LsWWlEPTB;NT63OlYzPyEQvF2= NELRUGxUSU6JRWK=
KGN MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTZwMEm5NlEh|ryP NWO4ZWR[W0GQR1XS
D-423MG MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DSZ2lEPTB;Nj60NFI5PCEQvF2= NIHlNnlUSU6JRWK=
ECC10 MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XoV2lEPTB;Nz6xNFExOSEQvF2= MoXiV2FPT0WU
TE-5 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7rTWM2OD15LkSxNlk5KM7:TR?= NVLse3h2W0GQR1XS
P12-ICHIKAWA MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETWdppKSzVyPUeuOFU2OjNizszN NX24copsW0GQR1XS
NCI-H82 NVS1cZZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r3O2lEPTB;Nz60OVcxOSEQvF2= MnXpV2FPT0WU
NCI-H1993 M1rGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHxTWM2OD15LkizNFY{KM7:TR?= M2DKfnNCVkeHUh?=
RH-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrTXnVKSzVyPUeuPFUzPDRizszN M4LBcHNCVkeHUh?=
SW948 M{L3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrXTWM2OD15Lkm2NFQ6KM7:TR?= NWm5SGNFW0GQR1XS
CAL-33 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\vZ2lEPTB;Nz65PVk{QCEQvF2= M3m1dXNCVkeHUh?=
U-266 M1qyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfGeXdmUUN3ME24MlE2Pzd5IN88US=> NHHDU|RUSU6JRWK=
CAL-72 M162SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRThwMkCzNkDPxE1? MlX1V2FPT0WU
SNU-423 NY\NRphDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELpPFdKSzVyPUmuN|Y3PjZizszN MlnYV2FPT0WU
KG-1 NUC3bo5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknPTWM2OD17LkW4OFU3KM7:TR?= MYjTRW5ITVJ?
HCC1395 NWHNSZFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHPTWM2OD17LkmyN|UzKM7:TR?= NEPBS4tUSU6JRWK=
BE-13 NHj3[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnrXpoyUUN3ME2xNE45QDl{IN88US=> NVnsPXE2W0GQR1XS
MKN7 NGjrXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\xTWM2OD1zMD65O|Y2KM7:TR?= MmDVV2FPT0WU
697 NYnBO4FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33BTWlEPTB;MUGuNVQ4OiEQvF2= NGHKSXNUSU6JRWK=
LU-135 MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvhXIZKSzVyPUGxMlI{ODdizszN NIjWN3ZUSU6JRWK=
ES7 MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nPZmlEPTB;MUGuN|MyOyEQvF2= NWrVOGp{W0GQR1XS
SK-HEP-1 NE[4OnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDjdVRKSzVyPUGxMlc3PDZizszN NVfPV49nW0GQR1XS
BEN NV\4NFluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnuXmJnUUN3ME2xNU45PTFizszN MVLTRW5ITVJ?
NCI-H1770 Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmqzTWM2OD1zMj6xNlYh|ryP MlXNV2FPT0WU
SW13 M{S1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nUPWlEPTB;MUKuNVU1OSEQvF2= NIrkbG1USU6JRWK=
MZ1-PC NIm0dW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTF{LkW0OVIh|ryP M1jSd3NCVkeHUh?=
Mo-T NFnNXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfTOGZHUUN3ME2xNk44PDJzIN88US=> MYTTRW5ITVJ?
HLE NXzNZ|VST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT5T2d6UUN3ME2xNk45OjF3IN88US=> NX;nXndJW0GQR1XS
RCC10RGB MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPYOGlKSzVyPUGzMlY4OSEQvF2= NGfwfWFUSU6JRWK=
COLO-320-HSR M3izSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DPWGlEPTB;MUOuO|M5OSEQvF2= NHrzSFFUSU6JRWK=
BHT-101 MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rDOWlEPTB;MUOuPFM1PSEQvF2= M2nJOHNCVkeHUh?=
OCUB-M NUi5Tlh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTF2LkG2NFIh|ryP MVnTRW5ITVJ?
MEG-01 Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTF2LkO3NFgh|ryP NVnlO4ZpW0GQR1XS
RS4-11 MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fNdWlEPTB;MUSuO|QzKM7:TR?= MXXTRW5ITVJ?
MN-60 NETDe|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPnfW1tUUN3ME2xOE44QDl2IN88US=> NGTDVoVUSU6JRWK=
NCI-H1304 NFvBRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nleWlEPTB;MUWuNFQzPSEQvF2= NEHNfGRUSU6JRWK=
Ramos-2G6-4C10 NVzRTohxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjXOlBIUUN3ME2xOU4xPThzIN88US=> MWjTRW5ITVJ?
NCI-H2342 MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHnbolKSzVyPUG1MlIxPDRizszN MUXTRW5ITVJ?
LAN-6 NGTHZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF3LkS0NVQh|ryP MofjV2FPT0WU
JVM-2 MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3j3TWlEPTB;MUWuOVc1QCEQvF2= MoX2V2FPT0WU
P30-OHK MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTF4LkC2NVQh|ryP MUXTRW5ITVJ?
C-33-A MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF4Lk[yNVQh|ryP M{LrV3NCVkeHUh?=
RPMI-8866 NWDMXWRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17jbWlEPTB;MU[uPFQ6PiEQvF2= NXfMV|VnW0GQR1XS
NCI-H630 NEHDdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjjPVBKSzVyPUG2Mlg2OzdizszN NFznR5hUSU6JRWK=
KYSE-140 M2LZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjOUXJ2UUN3ME2xO{4zODJ6IN88US=> NU[0[lhOW0GQR1XS
T84 NYC1foJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTF6Lki2PVUh|ryP NGHadVlUSU6JRWK=
KU-19-19 NEjmdZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTF6Lkm2NFgh|ryP MVzTRW5ITVJ?
BALL-1 M2jJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rrT2lEPTB;MUmuN|M6QSEQvF2= MnnxV2FPT0WU
Calu-6 M4K0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\keWlEPTB;MUmuOFkzKM7:TR?= MkL3V2FPT0WU
EGI-1 NYDTSnc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1yyS2lEPTB;MUmuOVk5KM7:TR?= MYPTRW5ITVJ?
MFH-ino M1S0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXpTWM2OD1zOT63OFU1KM7:TR?= MoTMV2FPT0WU
GB-1 MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\oTWM2OD1{MD6zOVM2KM7:TR?= NFrJRmxUSU6JRWK=
NCI-H1693 M{TDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3e3emlEPTB;MkCuOlUxPSEQvF2= NHP0RXFUSU6JRWK=
SW1116 Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DKN2lEPTB;MkCuPVM3OiEQvF2= NUjWc4hnW0GQR1XS
H-EMC-SS MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJ{LkC0OUDPxE1? NYnxS3BiW0GQR1XS
D-502MG Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\BTWM2OD1{Mj64NlYyKM7:TR?= NF3mNHBUSU6JRWK=
IA-LM MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzzSnRYUUN3ME2yN{4zPDl|IN88US=> M1PHcXNCVkeHUh?=
SW1463 NIPTZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TWbmlEPTB;MkOuO|kh|ryP MUnTRW5ITVJ?
JAR M3HiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj4UGZKSzVyPUK0MlMzQTNizszN MoruV2FPT0WU
HT NHzieWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWCwW2RJUUN3ME2yOE41PzV|IN88US=> MX3TRW5ITVJ?
LCLC-103H M3XYVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJ2Lki0OFkh|ryP MmLtV2FPT0WU
SNU-449 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJ2Lki3OFEh|ryP MYLTRW5ITVJ?
KE-37 NYXLN4YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTJ3LkC5Nlgh|ryP M3W1SHNCVkeHUh?=
NCI-H1623 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz2SmRMUUN3ME2yO{4yOzB|IN88US=> NFq5[ZNUSU6JRWK=
MOLT-13 NIX6c5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Dx[mlEPTB;MkeuN|UyPiEQvF2= M3jHSnNCVkeHUh?=
COLO-741 NIfyO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu4[JJKSzVyPUOxMlM{OzNizszN MkLLV2FPT0WU
NB6 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTN{LkK4O|Yh|ryP NXzwU5Y3W0GQR1XS
MOLT-16 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fEU2lEPTB;M{OuNFA2PSEQvF2= MmLKV2FPT0WU
IST-MES1 MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TqN2lEPTB;M{SuNFU1OSEQvF2= MYLTRW5ITVJ?
A4-Fuk MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\JTWM2OD1|NT6wOlYh|ryP NH3QbGRUSU6JRWK=
CAL-85-1 NHfYW5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PUb2lEPTB;M{WuNlgyPyEQvF2= NInmZYdUSU6JRWK=
CCRF-CEM MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Xrc2lEPTB;M{euNVU{PiEQvF2= M12ySXNCVkeHUh?=
HAL-01 M{HVSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrFUZNqUUN3ME2zPE41QDh7IN88US=> NUezd|hKW0GQR1XS
HEL NWLKS3ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLGXVRKSzVyPUSzMlM1ODlizszN MV\TRW5ITVJ?
EW-1 MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTWPVU3UUN3ME20N{41PzZ6IN88US=> NYjFeXc3W0GQR1XS
MDA-MB-231 MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTR3LkGxPVkh|ryP MkPKV2FPT0WU
ABC-1 NE\5VZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTR4Lki1N|gh|ryP MoPSV2FPT0WU
NCI-H446 M1;semdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjJTWM2OD12OD61NFU5KM7:TR?= Mn:0V2FPT0WU
MHH-PREB-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTR7Lk[wNFch|ryP NEGwSHlUSU6JRWK=
DOHH-2 MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfRfmpKSzVyPUS5MlY3PTZizszN NUX4bW9GW0GQR1XS
GCT MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjMTWM2OD12OT62PVc3KM7:TR?= NITpOFlUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo 17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. [1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. [2]

Protocol

Kinase Assay:[1]
+ Expand

Hsp90 binding assays:

Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:[1]
+ Expand
  • Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 5 days
  • Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A490) of wells not containing cells is subtracted. Percentage of viable cells = (A490 of 17-AAG treated sample/A490 untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6
  • Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle
  • Dosages: ~50 mg/kg
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (170.73 mM)
Ethanol 5 mg/mL (8.53 mM)
Water Insoluble
In vivo Add solvents individually and in order:
5%DMSO+corn oil
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 585.69
Formula

C31H43N3O8

CAS No. 75747-14-7
Storage powder
Synonyms CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00577889 Completed Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage IV Pancreatic Cancer National Cancer Institute (NCI) March 2008 Phase 2
NCT00546780 Completed Multiple Myeloma Bristol-Myers Squibb February 2008 Phase 3
NCT00093496 Completed Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer National Cancer Institute (NCI) October 2007 Phase 2
NCT00514371 Completed Multiple Myeloma Bristol-Myers Squibb August 2007 Phase 2|Phase 3
NCT00779428 Completed Advanced Malignancies Bristol-Myers Squibb July 2006 Phase 2
NCT00354185 Terminated Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia National Cancer Institute (NCI) May 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?

  • Answer:

    17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Tags: buy Tanespimycin (17-AAG) | Tanespimycin (17-AAG) supplier | purchase Tanespimycin (17-AAG) | Tanespimycin (17-AAG) cost | Tanespimycin (17-AAG) manufacturer | order Tanespimycin (17-AAG) | Tanespimycin (17-AAG) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID